TY - JOUR
T1 - Evaluation and Counseling of Teratogenic Risk
T2 - The Motherisk Approach
AU - Koren, Gideon
AU - Graham, Karen
AU - Feigenbaum, Annette
AU - Einarson, Tom
PY - 1993/10
Y1 - 1993/10
N2 - The authors present a new approach for evaluation and counseling of teralogenic risk. The Motherisk program in Toronto presently deals with 60 inquiries per day from the public and health professionals. Most calls are answered through the telephone, and 16–20 women per week are scheduled for our clinic following exposure to known or suspected teratogens, to new drugs with sparse information, to chronic drug therapy, or drugs of abuse. Also seen in clinic are women who want to be counseled or whose physicians want them to meet us due to high levels of anxiety. Since its inception in 1985 the Program has been very effective in preventing unnecessary terminations of otherwise wanted pregnancies. In addition to the clinical service we follow-up the outcome of these prospectively collected exposures, thus creating a large data base necessary to verify safety/risk of various agents. During the last 2 years Motherisk has completed singly, or in collaboration, large prospective studies on gestational exposure to lithium, antiepileptics, cocaine, and fluexitime. To study the reproductive risks of cocaine we compared first-trimester exposure to cocaine with two control groups. Infants exposed to cocaine did not have higher rates of any adverse perinatal outcome. Their cognitive function at 18 months of age was identical to the control infants. Meta-analysis of all studies assessing gestational risks of cocaine reveals that the results of these studies were dependent on the type of comparison conducted. When babies exposed to cocaine were compared with middle class nonusers, the cocaine groups seemed to be more often different from their controls. Conversely, when cocaine-exposed infants were compared with babies of women exposed to other drugs of abuse but not cocaine, most of these differences cancelled out, suggesting that clustering of other risk factors may cause some of these adverse effects.
AB - The authors present a new approach for evaluation and counseling of teralogenic risk. The Motherisk program in Toronto presently deals with 60 inquiries per day from the public and health professionals. Most calls are answered through the telephone, and 16–20 women per week are scheduled for our clinic following exposure to known or suspected teratogens, to new drugs with sparse information, to chronic drug therapy, or drugs of abuse. Also seen in clinic are women who want to be counseled or whose physicians want them to meet us due to high levels of anxiety. Since its inception in 1985 the Program has been very effective in preventing unnecessary terminations of otherwise wanted pregnancies. In addition to the clinical service we follow-up the outcome of these prospectively collected exposures, thus creating a large data base necessary to verify safety/risk of various agents. During the last 2 years Motherisk has completed singly, or in collaboration, large prospective studies on gestational exposure to lithium, antiepileptics, cocaine, and fluexitime. To study the reproductive risks of cocaine we compared first-trimester exposure to cocaine with two control groups. Infants exposed to cocaine did not have higher rates of any adverse perinatal outcome. Their cognitive function at 18 months of age was identical to the control infants. Meta-analysis of all studies assessing gestational risks of cocaine reveals that the results of these studies were dependent on the type of comparison conducted. When babies exposed to cocaine were compared with middle class nonusers, the cocaine groups seemed to be more often different from their controls. Conversely, when cocaine-exposed infants were compared with babies of women exposed to other drugs of abuse but not cocaine, most of these differences cancelled out, suggesting that clustering of other risk factors may cause some of these adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=84965510075&partnerID=8YFLogxK
U2 - 10.1177/089719009300600509
DO - 10.1177/089719009300600509
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84965510075
SN - 0897-1900
VL - 6
SP - 245
EP - 251
JO - Journal of Pharmacy Practice
JF - Journal of Pharmacy Practice
IS - 5
ER -